Drugs / FLUAD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03330132 | Oct 2017 → Dec 2025 | influenza | The University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLUAD | “0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern...” NCT03330132 ↗ |
| Modality | Vaccine | “MF59-adjuvanted vaccine” NCT03330132 ↗ |